Volume 28, Issue 2 - Generics and biosimilars

Biosimilar development – an overview

Author: Diana Radovan

Abstract

Download the full article

References

1. Tabernero J, Vyas M, Giualini R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016. 1: 1–5.
2. European Medicines Agency. Biosimilar medicines - overview [cited 2019 Mar 06] Available from: https://www.ema.europa.eu/en/humanregulatory/ overview/biosimilarmedicines- overview.
3. Pfizer Biosimilars [cited 2019 Mar 05] Available from: Available from: https://www.pfizerbiosimilars.com/ characteristics-of-biosimilars.
4. Ramzan A. The future of biosimilars – monoclonal antibodies and beyond. Regulatory Rapporteur. 2015;12(9):5–9.
5. FDA Draft Guidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act [cited 2019 Mar 06] Available from: Available from: https://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM407844.pdf
6. GABI Report. Biosimilars Marketed in Europe [cited 2019 Mar 06] Available from: Available from: http://www.gabionline.net/ Reports/ Biosimilars-marketed-in-Europe.
7. First Biosimilar Approved in the United Stated [cited 2019 Mar 06] Available from: Available from: https://www.pharmacytimes.com/product -news/first-biosimilar-approved-in-unitedstates.
8. EMEA/CHMP/BMWP/42832/2005 Rev1 Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues [cited 2019 Mar 06] Available from: Available from: https://www.ema.europa.eu/en/ documents/scientific-guideline/guidelinesimilar- biological-medicinal-productscontaining- biotechnology-derived-proteins -active_en-2.pdf.
9. FDA Listing of Biosimilar Guidances [cited 2019 Mar 06]. Available from: Available from: https://www.fda.gov/drugs/guidancecom plianceregulatoryinformation/guidances/ ucm290967.htm.
10. World Health Organization. Biologicals – Similar Biotherapeutic Products [cited 2019 Mar 06]. Available from: Available from: https://www.who.int/biologicals/biothera peutics/similar_biotherapeutic_products/ en/.
11. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union L 378/1.
12. US Food and Drug Administration. Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans Guidance for Industry. Draft Guidance. Revision 1; March 2016. [cited 2019 Mar 06]. Available from: Available from: https://www.fda.gov/downloads/drugs/ guidances/ucm360507.pdf.
13. Radovan B, Beeby B. Writing pediatric study plans (PSPs) – the impact of the revised 2016 FDA draft guidance. J Clin Stud. 2018;10(4):20–5.
14. EMA/CHMP/138502/2017 Draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development [cited 2019 Mar 06]. Available from: Available from: https://www.ema.europa.eu/en/ statistical-methodology-comparativeassessment- quality-attributes-drugdevelopment.
15. FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product [cited 2019 Mar 06]. Available from: Available from: https://www.fda.gov/downloads/drugs/ guidances/ucm291134.pdf.
16. Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015;44(6):S2–S8.
17. Balfour A, Schmitt S. Statistical principles in biosimilar development. Med Writ. 2019;28(2):28–32.
18. GABI Journal Editor. USA and Europe differ in interchangeability of biosimilars. GABI J. 2017;6(4):183–4.
19. Brauburger K, Heisel-Stöhr S. Writing biosimilar clinical study reports and submission documents – what to expect and what to consider. Med Writ. 2019;28(2):33–8.
20. von Bruchausen T, Prechtel K, Rechsteiner S. Same but different: Basic tools for biosimilar and generic pharmacovigilance writing. Med Writ. 2019;28(2):45-52.
21. McMinn D, Scott C, Jeffs B. Layperson materials in the sphere of biosimilars and generic medicines. Med Writ. 2019;28(2):53–6.
22. GABI Online – Generics and biosimilars initiative. Pfizer drops five preclinical biosimilar programmes [cited 2019 Mar 06]. Available from: Available from: http://www.gabionline.net/Biosimilars/ General/Pfizer-drops-five-preclinicalbiosimilar- programmes.